Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas

Cancer Genetics and Cytogenetics

Volumn 184, Issue 2, 2008, Pages 77-86

  Reddy, Kavita S ^a  

^a Genzyme Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GROWTH; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOMA; HUMAN; HUMAN TISSUE; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TETRAPLOIDY;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; COHORT STUDIES; FEMALE; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 46249132656     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.03.009     Document Type: Article

References (41)

1. CBTRUS. 2004-2005 statistical report: primary brain tumors in the United States, 1997-2001 (years data collected). Chicago: Central Brain Tumor Registry of the United States, 2004 [Available at http://www.cbtrus.org/reports/reports.html].
2. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and genetics of tumours of the nervous system, 2nd ed. World Health Organization Classification of Tumours (2000), IARC Press, Lyon
3. Collins V.P. Mechanisms of disease: genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 4 (2007) 362-374
4. Cairncross J.G., and Macdonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23 (1988) 360-364
5. Reifenberger J., Reifenberger G., Liu L., James C.D., Wechsler W., and Collins V.P. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145 (1994) 1175-1190
6. Nagasaka T., Gunji M., Hosokai N., Hayashi K., Ikeda H., Ito M., and Inao S. FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma. Brain Tumor Pathol 24 (2007) 1-5
7. Griffin C.A., Burger P., Morsberger L., Yonescu R., Swierczynski S., Weingart J.D., and Murphy K.M. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65 (2006) 988-994
8. Jenkins R.B., Blair H., Ballman K.V., Giannini C., Arusell R.M., Law M., Flynn H., Passe S., Felten S., Brown P.D., Shaw E.G., and Buckner J.C. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66 (2006) 9852-9861
9. Reifenberger G., and Louis D.N. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62 (2003) 111-126
10. Perry A., Fuller C.E., Banerjee R., Brat D.J., and Scheithauer B.W. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8 (2003) a1-a9
11. Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., Hammond R.R., Silver J.S., Stark P.C., Macdonald D.R., Ino Y., Ramsay D.A., and Louis D.N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
12. Jaeckle K.A., Ballman K.V., Rao R.D., Jenkins R.B., and Buckner J.C. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 24 (2006) 1246-1252
13. Cairncross G., Berkey B., Shaw E., Jenkins R., Scheithauer B., Brachman D., Buckner J., Fink K., Souhami L., Laperierre N., Mehta M., and Curran W. Intergroup Radiation Therapy Oncology Group Trial 9402. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24 (2006) 2707-2714
14. van den Bent M.J., Carpentier A.F., Brandes A.A., Sanson M., Taphoorn M.J., Bernsen H.J., Frenay M., Tijssen C.C., Grisold W., Sipos L., Haaxma-Reiche H., Kros J.M., van Kouwenhoven M.C., Vecht C.J., Allgeier A., Lacombe D., and Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 (2006) 2715-2722
15. Möllemann M., Wolter M., Felsberg J., Collins V.P., and Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113 (2005) 379-385
16. Gupta M., Djalilvand A., and Brat D.J. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol 124 (2005) 755-768
17. Hoang-Xuan K., He J., Huguet S., Mokhtari K., Marie Y., Kujas M., Leuraud P., Capelle L., Delattre J.Y., Poirier J., Broët P., and Sanson M. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57 (2001) 1278-1281
18. Sasaki H., Zlatescu M.C., Betensky R.A., Ino Y., Cairncross J.G., and Louis D.N. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159 (2001) 359-367
19. Ino Y., Betensky R.A., Zlatescu M.C., Sasaki H., Macdonald D.R., Stemmer-Rachamimov A.O., Ramsay D.A., Cairncross J.G., and Louis D.N. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7 (2001) 839-845
20. Huang H., Okamoto Y., Yokoo H., Heppner F.L., Vital A., Fevre-Montange M., Jouvet A., Yonekawa Y., Lazaridis E.N., Kleihues P., and Ohgaki H. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 23 (2004) 6012-6022
21. Ueki K., Nishikawa R., Nakazato Y., Hirose T., Hirato J., Funada N., Fujimaki T., Hojo S., Kubo O., Ide T., Usui M., Ochiai C., Ito S., Takahashi H., Mukasa A., Asai A., and Kirino T. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8 (2002) 196-201
22. Perry A., Aldape K.D., George D.H., and Burger P.C. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 101 (2004) 2318-2326
23. Walker C., du Plessis D.G., Joyce K.A., Fildes D., Gee A., Haylock B., Husband D., Smith T., Broome J., and Warnke P.C. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 57 (2005) 855-865
24. Johnson M.D., Vnencak-Jones C.L., Toms S.A., Moots P.M., and Weil R. Allelic losses in oligodendroglial and oligodendroglioma-like neoplasms: analysis using microsatellite repeats and polymerase chain reaction. Arch Pathol Lab Med 127 (2003) 1573-1579
25. Fallon K.B., Palmer C.A., Roth K.A., Nabors L.B., Wang W., Carpenter M., Banerjee R., Forsyth P., Rich K., and Perry A. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63 (2004) 314-322
26. van den Bent M.J., Looijenga L.H., Langenberg K., Dinjens W., Graveland W., Uytdewilligen L., Sillevis Smitt P.A., Jenkins R.B., and Kros J.M. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97 (2003) 1276-1284
27. Smith J.S., Perry A., Borell T.J., Lee H.K., O'Fallon J., Hosek S.M., Kimmel D., Yates A., Burger P.C., Scheithauer B.W., and Jenkins R.B. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18 (2000) 636-645
28. Hesser D.P. American Brain Tumor Association. Oligodendroglioma and oligoastrocytoma, 7th rev. ed. Focusing on Tumors (2007), ABTA, Des Plaines, IL. http://www.abta.org/siteFiles/SitePages/BE237E81490FDB6286AF83C71D912A42.pdf ]
29. Kreiger P.A., Okada Y., Simon S., Rorke L.B., Louis D.N., and Golden J.A. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol (Berl) 109 (2005) 387-392
30. Raghavan R., Balani J., Perry A., Margraf L., Vono M.B., Cai D.X., Wyatt R.E., Rushing E.J., Bowers D.C., Hynan L.S., and White III C.L. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62 (2003) 530-537
31. Schwartzbaum J.A., Fisher J.L., Aldape K.D., and Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2 (2006) 494-503
32. Felsberg J., Erkwoh A., Sabel M.C., Kirsch L., Fimmers R., Blaschke B., Schlegel U., Schramm J., Wiestler O.D., and Reifenberger G. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14 (2004) 121-130
33. Okamoto Y., Di Patre P.L., Burkhard C., Horstmann S., Jourde B., Fahey M., Schüler D., Probst-Hensch N.M., Gazi Yasargil M., Yonekawa Y., Lütolf U.M., Kleihues P., and Ohgaki H. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108 (2004) 49-56
34. Smith J.S., Tachibana I., Lee H.K., Qian J., Pohl U., Mohrenweiser H.W., Borell T.J., Hosek S.M., Soderberg C.L., von Deimling A., Perry A., Scheithauer B.W., Louis D.N., and Jenkins R.B. Mapping of the chromosome 19q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 29 (2000) 16-25
35. Schmidt M.C., Antweiler S., Urban N., Mueller W., Kuklik A., Meyer-Puttlitz B., Wiestler O.D., Louis D.N., Fimmers R., and von Deimling A. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61 (2002) 321-328
36. Qu M., Olofsson T., Sigurdardottir S., You C., Kalimo H., Nistér M., Smits A., and Ren Z.P. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113 (2007) 129-136
37. Pectasides D., Halikia A., Visvikis A., Bountouroglou N., Tzikas I., Iakovidou I., and Athanassiou A.E. Successful management of extracranial metastases from cerebral high-grade oligodendroglioma; report of a case with literature review. J BUON 7 (2002) 273-276
38. Macdonald D.R., O'Brien R.A., Gilbert J.J., and Cairncross J.G. Metastatic anaplastic oligodendroglioma. Neurology 39 (1989) 1593-1596
39. Dawson T.P. Pancytopenia from a disseminated anaplastic oligodendroglioma. Neuropathol Appl Neurobiol 23 (1997) 516-520
40. Gelpi E., Ambros I.M., Birner P., Luegmayr A., Drlicek A., Fischer I., Kleinert R., Maier H., Huemer M., Gatterbauer B., Anton J., Rössler K., Budka H., Ambros P.F., and Hainfellner J.A. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens. Mod Pathol 16 (2003) 708-715
41. Merrell R., Nabors L.B., Perry A., and Palmer C.A. 1p/19q chromosome deletions in metastatic oligodendroglioma. J Neurooncol 80 (2006) 203-207